Pulmonary disease due to nontuberculous mycobacteria current state and new insights

Chest

Volumn 148, Issue 6, 2015, Pages 1517-1527

  McShane, Pamela J ^a   Glassroth, Jeffrey ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 12; MACROLIDE; PRASTERONE; RIFAMPICIN; VITAMIN D; ANTIINFECTIVE AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIAN; ATYPICAL MYCOBACTERIOSIS; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BLACK PERSON; BODY HABITUS; CILIARY DYSKINESIA; CLINICAL FEATURE; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; HUMAN; IATROGENIC RISK FACTOR; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; LUNG INFECTION; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM XENOPEI; NONHUMAN; PACIFIC ISLANDER; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY CILIARY DYSFUNCTION; PRIORITY JOURNAL; PROGNOSIS; RAPID TEST; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SALVAGE THERAPY; ATYPICAL MYCOBACTERIUM; CLASSIFICATION; DISEASE MANAGEMENT; GENETICS; ISOLATION AND PURIFICATION; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOPHYSIOLOGY;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MANAGEMENT; HUMANS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84949009152     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0458     Document Type: Article

References (59)

1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest. 2008;133(1):243-251.
2. Pitchenik AE. PPD-tuberculin and PPD-Battey dual skin testing of hospital employees and medical students. South Med J. 1978; 71(8):917-918, 922.
3. Grifth DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous myco-bacterial diseases [published correction appears in Am J Respir Crit Care Med. 2007;175(7):744-745]. Am J Respir Crit Care Med. 2007;175(4):367-416.
4. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobac-terial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970-976.
5. Billinger ME, Olivier KN, Viboud C, et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis. 2009;15(10):1562-1569.
6. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in US Medicare benefciaries. Am J Respir Crit Care Med. 2012;185(8): 881-886.
7. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19(11):1889-1891.
8. Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis. 2008;14(3):378-384.
9. Andréjak C, Tomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181(5):514-521.
10. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med. 2014;190(5):581-586.
11. Adjemian J, Olivier KN, Seitz AE, Falkinham JO III, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med. 2012; 186(6):553-558.
12. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011;17(3):419-424.
13. McGarvey J, Bermudez LE. Pathogenesis of nontuberculous myco-bacteria infections. Clin Chest Med. 2002;23(3):569-583.
14. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000;11(4):321-333.
15. Sexton P, Harrison AC. Susceptibility to nontuberculous mycobac-terial lung disease. Eur Respir J. 2008;31(6):1322-1333.
16. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381(9877):1551-1560.
17. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185(2): 231-232.
18. Tettelin H, Davidson RM, Agrawal S, et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis. 2014;20(3):364-371.
19. Dirac MA, Horan KL, Doody DR, et al. Environment or host? A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186(7):684-691.
20. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178 (10): 1066-1074.
21. Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest. 2010;137(3):629-634.
22. O'Connell ML, Birkenkamp KE, Kleiner DE, Folio LR, Holland SM, Olivier KN. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest. 2012;141(4):1203-1209.
23. Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther. 2010;8(12):1359-1369.
24. Jeon K, Kim SY, Jeong BH, Chang B, Shin SJ, Koh WJ. Severe vitamin D def ciency is associated with non-tuberculous mycobacterial lung disease: a case-control study. Respirology. 2013;18(6):983-988.
25. Angerami M, Suarez G, Pascutti MF, Salomon H, Bottasso O, Quiroga MF. Modulation of the phenotype and function of Mycobacterium tuberculosis-stimulated dendritic cells by adrenal steroids. Int Immunol. 2013;25(7):405-411.
26. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepian-drosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol. 1991; 61 (2): 202-211.
27. Danley J, Kwait R, Peterson DD, et al. Normal estrogen, but low dehydroepiandrosterone levels, in women with pulmonary Mycobacterium avium complex. A preliminary study. Ann Am Thorac Soc. 2014;11(6):908-914.
28. Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med. 2013;187(12):1374-1381.
29. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis. 2009;15(10):1556-1561.
30. Gommans EP, Even P, Linssen CF, et al. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobac-teria: a retrospective cohort study. Respir Med. 2015; 109 (1): 137-145.
31. Rindi L, Garzelli C. Genetic diversity and phylogeny of Mycobacterium avium. Infect Genet Evol. 2014;21:375-383.
32. Tatano Y, Yasumoto K, Shimizu T, et al. Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis-and cavitary-type diseases. Eur J Clin Microbiol Infect Dis. 2010;29(7):801-806.
33. Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis. 2012;16(3):408-414.
34. Embil J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hyper-sensitivity pneumonitis or infection? Chest. 1997;111(3):813-816.
35. Khoor A, Leslie KO, Tazelaar HD, Helmers RA, Colby TV. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol. 2001; 115(5):755-762.
36. Gupta A, Rosenman KD. Hypersensitivity pneumonitis due to metal working fluids: sporadic or under reported? Am J Ind Med. 2006;49(6):423-433.
37. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. Clinical symptoms and survival in non-smoking and smoking HIV-negative patients with non-tuberculous mycobacte-rial isolation. Scand J Infect Dis. 2011;43(3):188-196.
38. Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009;13(10):1210-1218.
39. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185(5):575-583.
40. Grifth DE, Philley JV, Brown-Elliott BA, et al. The signif cance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. Chest. 2015; 147(5):1369-1375.
41. Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD. Clinical signif cance of a first positive nontuberculous mycobacteria culture in cystic fbrosis. Ann Am Thorac Soc. 2014;11(1):36-44.
42. Grifth DE, Brown-Elliott BA, Benwill JL, Wallace RJ Jr. Mycobacterium abscessus. "Pleased to meet you, hope you guess my name..". Ann Am Thorac Soc. 2015;12(3):436-439.
43. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810-818.
44. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917-925.
45. Tran AC, Halse TA, Escuyer VE, Musser KA. Detection of Mycobacterium avium complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings. Diagn Microbiol Infect Dis. 2014;79(1):43-48.
46. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother. 2012;18(4):436-443.
47. Brown-Elliott BA, Iakhiaeva E, Grifth DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013; 51 (10): 3389-3394.
48. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontu-berculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977-982.
49. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffth D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.
50. Griffth DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodef ciency virus-negative patients. J Infect Dis. 1998;178(1):121-126.
51. Griffth DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000;30(2):288-292.
52. Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191(1):96-103.
53. Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2):276-282.
54. Koh WJ, Jeon K, Lee NY, et al. Clinical signif cance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183(3):405-410.
55. Kim HS, Lee KS, Koh WJ, et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology. 2012;263(1):260-270.
56. van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6): 559-565.
57. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11(1):30-35.
58. Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015;148(2):499-506.
59. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fbrosis. Am J Respir Crit Care Med. 2013;188(7):807-812.